228 related articles for article (PubMed ID: 23517841)
1. Percutaneous revascularization for peripheral arterial disease: paclitaxel saves the day.
Mahmud E
JACC Cardiovasc Interv; 2013 Mar; 6(3):290-2. PubMed ID: 23517841
[No Abstract] [Full Text] [Related]
2. David versus Goliath: the first round.
Micari A; Vadalà G
JACC Cardiovasc Interv; 2014 Sep; 7(9):1057-9. PubMed ID: 25234680
[No Abstract] [Full Text] [Related]
3. Commentary: comparative effectiveness of paclitaxel-based femoropopliteal interventions.
Armstrong EJ
J Endovasc Ther; 2014 Jun; 21(3):369-72. PubMed ID: 24915583
[No Abstract] [Full Text] [Related]
4. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
[TBL] [Abstract][Full Text] [Related]
5. The THUNDER trial results: clearing the way or ushering the storm?
Jaff MR
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):109-10. PubMed ID: 25616823
[No Abstract] [Full Text] [Related]
6. Commentary: treatment of femoropopliteal in-stent restenosis for patients with diabetes: do we have an answer to the DEBATE?
Armstrong EJ; Laird JR
J Endovasc Ther; 2014 Feb; 21(1):9-11. PubMed ID: 24502478
[No Abstract] [Full Text] [Related]
7. Missing the Forest for the Trees?: Drug-Eluting Balloon Treatment for Infrapopliteal Disease.
Tsai TT
JACC Cardiovasc Interv; 2015 Oct; 8(12):1623-5. PubMed ID: 26493254
[No Abstract] [Full Text] [Related]
8. Commentary: how do we deal with dissection after angioplasty?
Fanelli F; Cannavale A; Gazzetti M; D'Adamo A
J Endovasc Ther; 2013 Dec; 20(6):801-4. PubMed ID: 24325696
[No Abstract] [Full Text] [Related]
9. Commentary: aligning incentives of payer, facility, and provider: the lynchpin of providing more cost-effective care.
Sternbergh WC
J Endovasc Ther; 2013 Dec; 20(6):826-7. PubMed ID: 24325700
[No Abstract] [Full Text] [Related]
10. Mortality After Paclitaxel Coated Balloon Angioplasty and Stenting of Superficial Femoral and Popliteal Artery in the Vascular Quality Initiative.
Bertges DJ; Sedrakyan A; Sun T; Eslami MH; Schermerhorn M; Goodney PP; Beck AW; Cronenwett JL; Eldrup-Jorgensen J
Circ Cardiovasc Interv; 2020 Feb; 13(2):e008528. PubMed ID: 32069110
[TBL] [Abstract][Full Text] [Related]
11. Drug-coated balloons--the importance of packing and dosing antiproliferative drugs.
Hehrlein C
Catheter Cardiovasc Interv; 2015 Aug; 86(2):287-8. PubMed ID: 26198065
[TBL] [Abstract][Full Text] [Related]
12. 1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
Micari A; Vadalà G; Castriota F; Liso A; Grattoni C; Russo P; Marchese A; Pantaleo P; Roscitano G; Cesana BM; Cremonesi A
JACC Cardiovasc Interv; 2016 May; 9(9):950-6. PubMed ID: 27151609
[TBL] [Abstract][Full Text] [Related]
13. Clinical Randomized Trial Evaluating Novel, Microcrystalline, and Biocompatible Polymer Paclitaxel-Coated Balloon for the Treatment of Femoropopliteal Occlusive Disease: The BIOPAC Trial.
Buszman PP; Nowakowski P; Milewski K; Orlik B; Żurakowski A; Ludyga T; Polczyk F; Dębiński M; Jelonek M; Kachel M; Gąsior M; Granada JF; Kiesz RS; Buszman PE
JACC Cardiovasc Interv; 2018 Dec; 11(23):2436-2438. PubMed ID: 30522679
[No Abstract] [Full Text] [Related]
14. In-stent restenosis management: the best is yet to come.
van den Berg JC
J Cardiovasc Surg (Torino); 2017 Aug; 58(4):508-517. PubMed ID: 28322039
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
Mehrotra S; Paramasivam G; Mishra S
Curr Cardiol Rep; 2017 Feb; 19(2):10. PubMed ID: 28185166
[TBL] [Abstract][Full Text] [Related]
16. How should I treat a restenosis after superficial femoral artery stenting?
Fusaro M; Cassese S; Byrne RA
EuroIntervention; 2013 Mar; 8(11):1342-5. PubMed ID: 23538161
[No Abstract] [Full Text] [Related]
17. 2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry.
Micari A; Cioppa A; Vadalà G; Castriota F; Liso A; Marchese A; Grattoni C; Pantaleo P; Cremonesi A; Rubino P; Biamino G
JACC Cardiovasc Interv; 2013 Mar; 6(3):282-9. PubMed ID: 23517840
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness of the paclitaxel-coated Luminor® balloon catheter versus an uncoated balloon catheter in superficial femoral and popliteal arteries in preventing vessel restenosis or reocclusion: study protocol for a randomized controlled trial.
Teichgräber U; Aschenbach R; Scheinert D; Zeller T; Brechtel K; Thieme M; Blessing E; Treitl M; Lichtenberg M; von Flotow P; Vogel B; Werk M; Riambau V; Wienke A; Lehmann T; Sixt S
Trials; 2016 Oct; 17(1):528. PubMed ID: 27793175
[TBL] [Abstract][Full Text] [Related]
19. ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery): A Randomized Trial.
Ott I; Cassese S; Groha P; Steppich B; Voll F; Hadamitzky M; Ibrahim T; Kufner S; Dewitz K; Wittmann T; Kasel AM; Laugwitz KL; Schunkert H; Kastrati A; Fusaro M
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28743787
[TBL] [Abstract][Full Text] [Related]
20. Commentary: intravascular ultrasound for femoropopliteal stenting: can it predict outcomes with current-generation stents?
Foley TR; Armstrong EJ
J Endovasc Ther; 2015 Jun; 22(3):350-1. PubMed ID: 25904483
[No Abstract] [Full Text] [Related]
[Next] [New Search]
